Conflict of interest: A.W received research funding from Celgene. The other authors declare no conflict of interest.
Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients
Article first published online: 16 MAY 2014
© 2014 Wiley Periodicals, Inc.
American Journal of Hematology
Volume 89, Issue 8, pages 795–802, August 2014
How to Cite
Govindaraj, C., Madondo, M., Kong, Y. Y., Tan, P., Wei, A. and Plebanski, M. (2014), Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients. Am. J. Hematol., 89: 795–802. doi: 10.1002/ajh.23746
- Issue published online: 14 JUL 2014
- Article first published online: 16 MAY 2014
- Accepted manuscript online: 23 APR 2014 12:06AM EST
- Manuscript Accepted: 21 APR 2014
- Manuscript Revised: 19 APR 2014
- Manuscript Received: 28 OCT 2013
- Victorian Cancer Agency, Leukemia Foundation of Australia, Celgene
- Senior NHMRC Fellowship
- Monash Graduate Scholarship (MGS) from Monash University
- Faculty of medicine international postgraduate scholarship from Monash University
- MGS from Monash University
Additional Supporting Information may be found in the online version of this article.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.